Current Status
Not Enrolled
Price
Free
Get Started

Program Director

Khalid Al Rasadi, MD

Program Director

Raul D Santos, MD, MSc, PhD

2020 Middle East Summit on Residual Cardiovascular Risk

Cardiovascular diseases remain the #1 cause of death and disability globally and are on the rise in developing regions of the world. Despite advances in the control of the classic risk factors like lowering LDL-Cholesterol and efforts to manage contributing disease factors such as diabetes, obesity and hypertension, patient risk for developing ASCVD can still remain high. This course was designed to educate on the complete examination and clinical approaches to the treatment of residual risk (RR) factors that may persist and ultimately continue to drive the patient’s potential for cardiovascular events.

The IAS is pleased to present thirteen (13) recordings from the live accredited sessions presented at the 2020 Middle East Residual Risk Cardiovascular Summit held in Dubai on February 21-22, 2020. This comprehensive educational event was designed for medical professionals in the clinical setting.

The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the speakers and participants for sharing their experience and for helping IAS to develop this global faculty of experts featured in the presentations.

Pre-activity information

Not available

Futuras terapias para o tratamento da dislipidemia (Video 9 – Future Therapies for Dyslipidemia Treatment)

See more...

Not available

Uso de inibidores de PCSK9 em pacientes com hipercolesterolemia familiar (Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients)

See more...

Not available

Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins

See more...

Not available

血脂異常治療的未來療法 (Video 9 – Future Therapies for Dyslipidemia Treatment)

See more...

Not available

在家庭高膽固醇血症患者中使用PCSK9抑製劑 (Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients)

See more...

Not available

急性冠狀動脈綜合症后早期使用單克隆PCSK9抑製劑的功效、可行性和安全性 (Video 7 – Efficacy, Feasibility and Safety of Early Use of Monoclonal PCSK9 Inhibitors After an Acute Coronary Syndrome)

See more...

Not available

PCSK9抑制对高风险患者的影响以及如何提高成本效益 (Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness)

See more...

Not available

阻斷迴圈PCSK9與單克隆抗體對動脈原脂蛋白的影響 (Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins)

See more...

Not available

如何安全是強烈的低密度脂蛋白-C 減少 (Video 4 – Safety of Intensive LDL-C Reduction)

See more...

Not available

對於 ASCVD 預防越低 LDL-C 越好 (Video 3 – For ASCVD Prevention the Lower The LDL-C the Better)

See more...

Not available

全球膽固醇控制的悲傷和不足的現實 (Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide)

See more...

Not available

LDL-C 是動脈粥樣硬化心血管疾病病因的證據 (Video 1 – Evidence of LDL-C as a Cause of Atherosclerotic Cardiovascular Disease)

See more...

Not available

Futuras terapias para el tratamiento de la dislipidemia (Video 9 – Future Therapies for Dyslipidemia Treatment)

See more...

Not available

Uso de inhibidores de PCSK9 en pacientes con hipercolesterolemia familiar (Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients)

See more...

Not available

Eficacia, viabilidad y seguridad del uso temprano de inhibidores monoclonales de PCSK9 después de un síndrome coronario agudo (Video 7 – Efficacy, Feasibility and Safety of Early Use of Monoclonal PCSK9 Inhibitors After an Acute Coronary Syndrome)

See more...

Not available

Impacto de la inhibición de PCSK9 en pacientes de muy alto riesgo y cómo aumentar la rentabilidad (Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness)

See more...

Not available

Impacto del bloqueo de la PCSK9 circulante con anticuerpos monoclonales sobre las lipoproteínas aterogénicas (Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins)

See more...

Not available

Seguridad de la reducción intensiva de LDL-C (Video 4 – Safety of Intensive LDL-C Reduction)

See more...

Not available

Para la prevención de ASCVD, cuanto menor sea el LDL-C, mejor (Video 3 – For ASCVD Prevention the Lower The LDL-C the Better)

See more...

Not available

La triste e inadecuada realidad del control del colesterol en todo el mundo (Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide)

See more...

« » page 1 / 9